EA035973B9 - Amino acid sequences directed against il-17a, il-17f and/or il-17a/f and polypeptides comprising the same - Google Patents

Amino acid sequences directed against il-17a, il-17f and/or il-17a/f and polypeptides comprising the same

Info

Publication number
EA035973B9
EA035973B9 EA201391632A EA201391632A EA035973B9 EA 035973 B9 EA035973 B9 EA 035973B9 EA 201391632 A EA201391632 A EA 201391632A EA 201391632 A EA201391632 A EA 201391632A EA 035973 B9 EA035973 B9 EA 035973B9
Authority
EA
Eurasian Patent Office
Prior art keywords
diseases
disease
autoimmune
polypeptide
human
Prior art date
Application number
EA201391632A
Other languages
English (en)
Other versions
EA201391632A1 (ru
EA035973B1 (ru
Inventor
Хейди Роммеларе
Йост Александер Колкман
Майкл Джон Скотт Сондерс
Анн Юньон
Йоланд Шватшко
Аманда Е.и. Праудфут
Ален Викари
Дени Брюникель
Лоран Шевале
Оливье Лежер
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46245559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA035973(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201391632A1 publication Critical patent/EA201391632A1/ru
Publication of EA035973B1 publication Critical patent/EA035973B1/ru
Publication of EA035973B9 publication Critical patent/EA035973B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Изобретение относится к полипептиду, который специфически связывается с человеческим IL-17A, человеческим IL-17F и/или человеческим IL-17A/F, к применению такого полипептида, к способу лечения заболевания и к фармацевтической композиции, содержащей его. Полипептид может быть использован для лечения заболевания, выбранного из группы, состоящей из системной красной волчанки, ревматоидного артрита, остеоартрита, юношеского хронического артрита, спондилоартропатий, системного склероза, идиопатических воспалительных миопатий, синдрома Шегрена, системного васкулита, саркоидоза, аутоиммунной гемолитической анемии, аутоиммунной тромбоцитопении, тиреоидита, сахарного диабета, иммуноопосредованных заболеваний почек, демиелинизирующих заболеваний центральной и периферической нервной системы, таких как рассеянный склероз, идиопатическая демиелинизирующая полинейропатия или синдром Гийена-Барре и хроническая воспалительная демиелинизирующая полинейропатия, болезней желчи и желчных путей, таких как инфекционный аутоиммунный хронический активный гепатит, первичный биллиарный цирроз, гранулематозный гепатит и склерозирующий холангит, воспалительного заболевания кишечника, глютенчувствительной энтеропатии и болезни Уиппла, аутоиммунных или иммуноопосредованных заболеваний кожи, включающих буллезные заболевания кожи, полиморфную эритему и контактный дерматит, псориаза, аллергических заболеваний, таких как астма, аллергический ринит, атопический дерматит, гиперчувствительность к пище и крапивница, иммунологических заболеваний легких, таких как эозинофильная пневмония, идиопатический легочный фиброз и гиперчувствительный пневмонит, связанных с трансплантацией заболеваний, включающих отторжение трансплантата и реакцию "трансплантат против хозяина".
EA201391632A 2011-05-05 2012-05-04 Amino acid sequences directed against il-17a, il-17f and/or il-17a/f and polypeptides comprising the same EA035973B9 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161482802P 2011-05-05 2011-05-05
PCT/EP2012/058313 WO2012156219A1 (en) 2011-05-05 2012-05-04 Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same

Publications (3)

Publication Number Publication Date
EA201391632A1 EA201391632A1 (ru) 2014-07-30
EA035973B1 EA035973B1 (ru) 2020-09-08
EA035973B9 true EA035973B9 (en) 2021-03-30

Family

ID=46245559

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391632A EA035973B9 (en) 2011-05-05 2012-05-04 Amino acid sequences directed against il-17a, il-17f and/or il-17a/f and polypeptides comprising the same

Country Status (24)

Country Link
US (4) US10017568B2 (ru)
EP (3) EP3363815A1 (ru)
JP (5) JP6628965B2 (ru)
KR (1) KR102083230B1 (ru)
CN (2) CN107098971B (ru)
AU (1) AU2012257942B8 (ru)
BR (1) BR112013028407B1 (ru)
CA (1) CA2834907C (ru)
CL (1) CL2013003090A1 (ru)
DK (1) DK2705058T3 (ru)
EA (1) EA035973B9 (ru)
ES (1) ES2662371T3 (ru)
HR (1) HRP20180380T1 (ru)
HU (1) HUE037225T2 (ru)
IL (1) IL228813B (ru)
LT (1) LT2705058T (ru)
MX (1) MX2013012844A (ru)
MY (1) MY167231A (ru)
NZ (1) NZ616761A (ru)
PT (1) PT2705058T (ru)
SG (2) SG10201606409TA (ru)
SI (1) SI2705058T1 (ru)
UA (1) UA117218C2 (ru)
WO (1) WO2012156219A1 (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3546483A1 (en) 2010-05-20 2019-10-02 Ablynx N.V. Biological materials related to her3
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP3441400B1 (en) * 2012-11-19 2022-07-20 Pieris Pharmaceuticals GmbH Novel specific-binding polypeptides and uses thereof
FR3007411B1 (fr) * 2013-06-21 2015-07-03 Agronomique Inst Nat Rech Anticorps monocatenaire a chaine lourde de camelide dirige contre la chromatine et utilisations
MX2016010729A (es) 2014-02-21 2016-10-26 Genentech Inc Anticuerpos biespecificos anti-il-13 / il-17 y sus usos.
CN113717280A (zh) 2014-05-16 2021-11-30 埃博灵克斯股份有限公司 改进的免疫球蛋白可变结构域
RU2723034C2 (ru) * 2014-05-22 2020-06-08 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Новые полипептиды со специфическим связыванием и пути их применения
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
GB201500463D0 (en) 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
AU2016209247B2 (en) 2015-01-21 2021-02-25 Inhibrx Biosciences, Inc. Non-immunogenic single domain antibodies
JP2018506275A (ja) 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
US11492396B2 (en) * 2015-10-27 2022-11-08 UCB Biopharma SRL Methods of treatment using anti-IL-17A/F antibodies
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
GB201612043D0 (en) 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
RU2771485C2 (ru) 2017-02-10 2022-05-04 Дженентек, Инк. Антитела против триптазы, их композиции и применения
CN108359011B (zh) * 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
CN107857818A (zh) * 2017-08-07 2018-03-30 上海科新生物技术股份有限公司 一种针对IL‑17和TNF‑α的双特异性融合蛋白
CN113603777B (zh) * 2018-02-12 2022-10-21 原启生物科技(上海)有限责任公司 Il17抗体及其应用
CN110003329B (zh) * 2019-04-12 2022-09-27 深圳普瑞金生物药业股份有限公司 多肽、il17a/f单域抗体、核苷酸序列及试剂盒
WO2022012636A1 (en) * 2020-07-15 2022-01-20 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric il17a and/or il17f
WO2022040506A2 (en) * 2020-08-21 2022-02-24 Yale University Nanobody compositions and methods of use of the same
WO2023035272A1 (zh) * 2021-09-13 2023-03-16 深圳华普药物研发有限公司 一种il17抗体及其制备方法和应用
CN114380906B (zh) * 2022-03-25 2022-06-14 南京融捷康生物科技有限公司 一种抗il-17a的单域抗体及其用途
WO2023186174A1 (en) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Topical formulation comprising an il-17a binding molecule and uses thereof
AR129111A1 (es) 2022-04-22 2024-07-17 Moonlake Immunotherapeutics Ag Métodos para lograr un control seguro y sostenido de afecciones dependientes de il-17 en sujetos que responden a tratamiento con un nanocuerpo anti-il-17a/f
CN115093483A (zh) * 2022-06-17 2022-09-23 国药中生生物技术研究院有限公司 Il-17ra融合蛋白、药物组合物、注射剂及其应用
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
EP4393948A1 (en) 2022-12-28 2024-07-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic vhh antibodies cross-neutralizing the il-17a and il-17f homodimers as well as the il-17af heterodimer
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
CN116769027B (zh) * 2023-06-09 2023-12-01 康元医疗科技(大连)有限公司 一种抗il-17纳米抗体、多肽及其应用
CN117843776B (zh) * 2023-12-21 2024-08-30 北京贝来药业有限公司 抗体分子、核酸、制药用途及炎性疾病治疗方法
CN117843805B (zh) * 2023-12-29 2024-09-06 北京贝来药业有限公司 抗体分子、核酸分子、药物组合物以及应用
CN117843801B (zh) * 2023-12-29 2024-08-02 北京贝来药业有限公司 以白介素家族成员为靶点的新型抗体以及下游产品
CN117820481A (zh) * 2023-12-29 2024-04-05 北京贝来药业有限公司 新型抗体分子及其制药用途
CN117843804B (zh) * 2023-12-29 2024-08-20 北京贝来药业有限公司 单域抗体串联分子及其序列、产品、制备和应用
CN118206654B (zh) * 2024-03-05 2024-09-20 北京贝来药业有限公司 用于疾病治疗的新型抗体及其产品和应用
CN117866903B (zh) * 2024-03-12 2024-06-04 北京贝来药业有限公司 单域抗体修饰的干细胞及其在疾病治疗中用途
CN117866905B (zh) * 2024-03-12 2024-06-04 北京贝来药业有限公司 基于纳米抗体基因修饰的干细胞及其制备方法和产品
CN117860786B (zh) * 2024-03-12 2024-06-04 北京贝来药业有限公司 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054059A1 (en) * 2004-11-19 2006-05-26 Ucb Pharma S.A. Neutralising antibody molecules having specificity for human il-17
WO2008047134A2 (en) * 2006-10-18 2008-04-24 Ucb Pharma S.A. Antibody molecules which bind il-17a and il-17f
WO2009136286A2 (en) * 2008-05-05 2009-11-12 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
WO2010025400A2 (en) * 2008-08-29 2010-03-04 Genentech, Inc. Cross-reactive and bispecific anti-el 17a/f antibodies

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
WO1993023537A1 (en) 1992-05-08 1993-11-25 Creative Biomolecules Chimeric multivalent protein analogues and methods of use thereof
EP0651805B1 (en) 1992-07-17 2006-12-13 Dana Farber Cancer Institute Method of intracellular binding of target molecules
EP1087013B1 (en) 1992-08-21 2009-01-07 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
JPH08511160A (ja) 1993-06-09 1996-11-26 ユニリーバー・ナームローゼ・ベンノートシャープ 形質転換真カビによってＳｃＦｖフラグメントを含んでなる融合タンパク質を生産する方法
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6091639A (en) 1993-08-27 2000-07-18 Kabushiki Kaisha Toshiba Non-volatile semiconductor memory device and data programming method
JPH10501681A (ja) 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート 核酸送達システムならびにその合成および使用方法
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
AU727480B2 (en) 1995-07-19 2000-12-14 Genetics Institute, Llc Human CTLA-8 and uses of CTLA-8-related proteins
US6902735B1 (en) 1995-07-19 2005-06-07 Genetics Institute, Llc Antibodies to human IL-17F and other CTLA-8-related proteins
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
EP1027073A2 (en) 1996-11-19 2000-08-16 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
US20020177188A1 (en) 1998-05-15 2002-11-28 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
CN1203178C (zh) 1997-10-27 2005-05-25 尤尼利弗公司 多价抗原结合蛋白
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
AU3295299A (en) 1998-02-19 1999-09-06 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
US6486303B1 (en) 1998-04-14 2002-11-26 University Of Medicine & Dentistry Of New Jersey Method for making hormone heterodimers
AU6277799A (en) 1998-10-02 2000-04-26 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and usesthereof
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
EP1144616B2 (en) 1999-01-19 2009-01-14 Unilever Plc Method for producing antibody fragments
EP1053751A1 (en) 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
CA2391374A1 (en) 1999-12-23 2001-06-28 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
CA2405557C (en) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US6741957B1 (en) 2000-07-21 2004-05-25 Daimlerchrysler Corporation Analytical tire model for vehicle durability and ride comfort analysis
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP2316951A1 (en) 2001-01-17 2011-05-04 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002064739A2 (en) 2001-02-09 2002-08-22 Johns Hopkins University A cytokine related structurally to il-17
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2002355477B2 (en) 2001-08-03 2008-09-25 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
KR100599789B1 (ko) 2001-12-03 2006-07-12 삼성에스디아이 주식회사 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
WO2003054016A2 (en) 2001-12-21 2003-07-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
EP1461085A2 (en) 2002-01-03 2004-09-29 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunoconjugates useful for treatment of tumours
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US20080241166A1 (en) 2002-06-28 2008-10-02 Domantis Limited Ligands that bind a receptor
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
EP2267032A3 (en) 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2003285578B2 (en) 2002-12-03 2010-07-15 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
WO2004060965A2 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
HUE045709T2 (hu) 2003-07-08 2020-01-28 Genentech Inc Antagonista antitestek IL-17A/F heterológ polipeptidekhez
EP1656128A4 (en) 2003-08-12 2007-02-28 William M Yarbrough SINGLE ACNE TREATMENT AND METHOD OF USE
US20060263353A1 (en) 2003-08-20 2006-11-23 Lawson Alastair D G Methods for obtaining antibodies
US20050279676A1 (en) 2004-06-21 2005-12-22 Izzy Zuhair A Fluid filter assembly for a dispensing faucet
US20060008601A1 (en) 2004-06-25 2006-01-12 Zeik Douglas B Flexible laminate having an integrated pressure release valve
US7882839B2 (en) 2004-06-25 2011-02-08 Ambis Jr Edward J Custom mouthguard
LT2311874T (lt) 2004-07-22 2017-11-27 Erasmus University Medical Center Rotterdam Rišančiosios molekulės
CN100396019C (zh) 2004-07-31 2008-06-18 华为技术有限公司 移动终端数据源模拟方法
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
WO2006040154A2 (en) 2004-10-14 2006-04-20 Dublin City University Prokaryotic two hybrid system
MY142617A (en) 2004-12-23 2010-12-15 Domantis Ltd Dual specific ligands with increased serum half-life
EP1844073A1 (en) 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
TW200641353A (en) 2005-02-14 2006-12-01 Wyeth Corp Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
SI1888641T1 (sl) 2005-05-18 2012-05-31 Ablynx Nv Proteini ki vežejo serum albumin
WO2006122825A2 (en) 2005-05-20 2006-11-23 Ablynx Nv Single domain vhh antibodies against von willebrand factor
WO2007042289A2 (en) 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies™ and polypeptides against egfr and igf-ir
US20090252681A1 (en) 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2007112940A2 (en) 2006-03-31 2007-10-11 Ablynx N.V. Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
EP2010568A1 (en) 2006-04-14 2009-01-07 Ablynx N.V. Dp-78-like nanobodies
EP2044118A2 (en) 2006-06-13 2009-04-08 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
EP2040995A1 (en) 2006-06-26 2009-04-01 Aida Centre, S.L. Blister package integrating rfid based tags
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
EP2069402A2 (en) 2006-09-08 2009-06-17 Ablynx N.V. Serum albumin binding proteins with long half-lives
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
CA2666511A1 (en) 2006-10-11 2008-04-17 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and uses thereof
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
AU2007328900A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
EP2647388A1 (en) 2007-02-16 2013-10-09 Merrimack Pharmaceuticals, Inc. Antibodies Against ERBB3 and Uses Thereof
EA200901154A1 (ru) 2007-03-26 2010-04-30 Займодженетикс, Инк. Растворимые слитые белки il17ra/rc и родственные способы
WO2009023386A2 (en) 2007-07-06 2009-02-19 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
JP2011504740A (ja) 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
JP5373823B2 (ja) 2008-01-29 2013-12-18 アブリンクス エン．ヴェー． タンパク質及びポリペプチドを安定化する方法
US8217140B2 (en) 2008-04-17 2012-07-10 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
MY153893A (en) 2008-09-29 2015-04-15 Roche Glycart Ag Antibodies against human il17 and uses thereof
PE20160653A1 (es) 2009-03-05 2016-07-24 Abbvie Inc Proteinas de union a il-17
EP2424889B1 (en) 2009-04-30 2015-08-12 Ablynx N.V. Method for the production of domain antibodies
US8137671B2 (en) 2009-05-05 2012-03-20 Genentech, Inc. Anti-IL-17F antibodies
WO2010142551A2 (en) * 2009-06-12 2010-12-16 Ablynx N.V. Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family
JP5922025B2 (ja) 2009-10-30 2016-05-25 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−１７ａ拮抗物質
HUE035618T2 (en) 2010-01-15 2018-05-28 Kirin Amgen Inc Antibody presentation and therapeutic regimens
US8965476B2 (en) * 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
LT2625199T (lt) 2010-10-08 2018-03-12 Novartis Ag Psoriazės gydymo būdai panaudojant il-17 antagonistus
ES2804624T1 (es) 2010-11-05 2021-02-08 Novartis Ag Métodos de tratamiento de artritis psoriásica usando antagonistas de IL-17
CN103384682B (zh) 2011-01-14 2017-04-12 Ucb医药有限公司 结合il‑17a和il‑17f的抗体分子
TWI439451B (zh) 2011-03-24 2014-06-01 Hoffmann La Roche 雜環胺衍生物
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
MX2014004980A (es) 2011-10-24 2014-09-11 Abbvie Inc Inmunoaglutinantes biespecificos dirigidos contra tnf e il-17.
CN104245738B (zh) 2012-04-05 2018-02-02 弗·哈夫曼-拉罗切有限公司 针对人tweak和人il17的双特异性抗体及其用途
AR090626A1 (es) 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
LT2953969T (lt) 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
CL2015001213A1 (es) 2015-05-07 2015-07-10 Pontificia Universidad Católica De Chile Método ex vivo para predecir respuesta a un tratamiento inmunomodulador en pacientes con enfermedad inflamatoria, el cual comprende la cuantificación de las razones entre las concentraciones de citoquinas seleccionadas de ifn-gamma/il-17f, il17f/il-10, il-17f/ifn-gamma e il-10/il17f; y kit para llevar a cabo el método.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054059A1 (en) * 2004-11-19 2006-05-26 Ucb Pharma S.A. Neutralising antibody molecules having specificity for human il-17
WO2008047134A2 (en) * 2006-10-18 2008-04-24 Ucb Pharma S.A. Antibody molecules which bind il-17a and il-17f
WO2009136286A2 (en) * 2008-05-05 2009-11-12 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
WO2010025400A2 (en) * 2008-08-29 2010-03-04 Genentech, Inc. Cross-reactive and bispecific anti-el 17a/f antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARBABI GHAHROUDI, M. DESMYTER, A. WYNS, L. HAMERS, R. MUYLDERMANS, S.: "Selection and identification of single domain antibody fragments from camel heavy-chain antibodies", FEBS LETTERS, ELSEVIER, AMSTERDAM., NL, vol. 414, no. 3, 15 September 1997 (1997-09-15), NL, pages 521 - 526, XP004261105, ISSN: 0014-5793, DOI: 10.1016/S0014-5793(97)01062-4 *
HOLT, L.J. HERRING, C. JESPERS, L.S. WOOLVEN, B.P. TOMLINSON, I.M.: "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY., ELSEVIER PUBLICATIONS, CAMBRIDGE., GB, vol. 21, no. 11, 1 November 2003 (2003-11-01), GB, pages 484 - 490, XP004467495, ISSN: 0167-7799, DOI: 10.1016/j.tibtech.2003.08.007 *
VINCKE C�CILE; LORIS REMY; SAERENS DIRK; MARTINEZ-RODRIGUEZ SERGIO; MUYLDERMANS SERGE; CONRATH KATJA: "General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold.", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 284, no. 5, 30 January 2009 (2009-01-30), pages 3273 - 3284, XP009124408, ISSN: 0021-9258, DOI: 10.1074/jbc.M806889200 *

Also Published As

Publication number Publication date
EP4105231A1 (en) 2022-12-21
DK2705058T3 (en) 2018-03-05
JP2014516945A (ja) 2014-07-17
JP6628965B2 (ja) 2020-01-15
JP6768027B2 (ja) 2020-10-14
EA201391632A1 (ru) 2014-07-30
AU2012257942A2 (en) 2014-06-05
BR112013028407A2 (pt) 2016-11-29
CA2834907A1 (en) 2012-11-22
SG10201606409TA (en) 2016-09-29
US11773159B2 (en) 2023-10-03
CN103717618A (zh) 2014-04-09
UA117218C2 (uk) 2018-07-10
US20190100584A1 (en) 2019-04-04
IL228813A0 (en) 2013-12-31
WO2012156219A9 (en) 2013-04-18
MX2013012844A (es) 2013-11-20
NZ616761A (en) 2016-01-29
EP2705058A1 (en) 2014-03-12
AU2012257942B8 (en) 2015-09-17
AU2012257942B2 (en) 2015-08-20
PT2705058T (pt) 2018-03-20
CL2013003090A1 (es) 2014-10-10
AU2012257942A1 (en) 2013-05-02
CN107098971A (zh) 2017-08-29
WO2012156219A1 (en) 2012-11-22
LT2705058T (lt) 2018-04-10
MY167231A (en) 2018-08-14
EA035973B1 (ru) 2020-09-08
IL228813B (en) 2018-07-31
AU2012257942A8 (en) 2015-09-10
EP2705058B1 (en) 2018-01-10
JP7093380B2 (ja) 2022-06-29
US20220195031A1 (en) 2022-06-23
HUE037225T2 (hu) 2018-08-28
CA2834907C (en) 2023-03-07
KR20140132661A (ko) 2014-11-18
US20210130452A1 (en) 2021-05-06
ES2662371T3 (es) 2018-04-06
US20140314743A1 (en) 2014-10-23
JP2022137058A (ja) 2022-09-21
CN103717618B (zh) 2016-12-07
US10017568B2 (en) 2018-07-10
JP2018154628A (ja) 2018-10-04
HRP20180380T1 (hr) 2018-04-06
KR102083230B1 (ko) 2020-03-02
BR112013028407B1 (pt) 2021-11-23
CN107098971B (zh) 2020-07-10
SG194632A1 (en) 2013-12-30
SI2705058T1 (en) 2018-04-30
JP2024122989A (ja) 2024-09-10
EP3363815A1 (en) 2018-08-22
JP2020193195A (ja) 2020-12-03
US10829552B2 (en) 2020-11-10

Similar Documents

Publication Publication Date Title
EA035973B9 (en) Amino acid sequences directed against il-17a, il-17f and/or il-17a/f and polypeptides comprising the same
JP2014516945A5 (ru)
JP2010511056A5 (ru)
JP2010187677A5 (ru)
JP2020193195A5 (ru)
JP2010162017A5 (ru)
JP2018154628A5 (ru)
RU2009124453A (ru) Гетеродимерные полипептиды il-17 a/f и возможности их лечебного применения
JP2012516158A5 (ru)
HRP20171176T1 (hr) C5ar antagonisti
RU2017134274A (ru) Связывающие tslp белки
JP2017510575A5 (ru)
WO2007111714A3 (en) Il-21 antagonists
JP2014513953A5 (ru)
HRP20160638T1 (hr) Antigen vezujući proteini sposobni vezati timusni stromalni limfopoetin
JP2010505418A5 (ru)
NZ590466A (en) Treatment of inflammatory diseases with mammal beta defensins
SI2699601T1 (en) PROTITOLIC POLYPETIDES AS THE CD40 ANTAGONISTS
JP2016500250A5 (ru)
JP2011144177A5 (ru)
JP2010220614A5 (ru)
JP2014530611A5 (ru)
JP2010273685A5 (ru)
JP2009526084A5 (ru)
WO2007076200A3 (en) Antagonists of hmgb1 and/or rage and methods of use thereof

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

TH4A Publication of the corrected specification to eurasian patent